van der Does Anne M, Amatngalim Gimano D, Keijser Bart, Hiemstra Pieter S, Villenave Remi
Department of Pulmonology, Leiden University Medical Center, Leiden 2300 RC, The Netherlands.
Department of Pediatric Pulmonology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht 3508 AB, The Netherlands.
Vaccines (Basel). 2018 Jul 28;6(3):49. doi: 10.3390/vaccines6030049.
The respiratory tract harbours a variety of microorganisms, collectively called the respiratory microbiota. Over the past few years, alterations in respiratory and gut microbiota composition have been associated with chronic inflammatory diseases of the lungs. How these changes influence disease development and progression is an active field of investigation. Identifying and understanding host-microbiota interactions and factors contributing to these interactions could promote the development of novel therapeutic strategies aimed at restoring host-microbiota homeostasis. In this review, we discuss recent literature on host-microbiota interactions in the respiratory tract, with a specific focus on the influence of endogenous host defence peptides and proteins (HDPs) on the composition of microbiota populations in vivo and explore possible HDPs-related therapeutic approaches targeting microbiota dysbiosis in chronic inflammatory lung diseases.
呼吸道中存在着多种微生物，统称为呼吸道微生物群。在过去几年中，呼吸道和肠道微生物群组成的改变与肺部慢性炎症性疾病有关。这些变化如何影响疾病的发生和发展是一个活跃的研究领域。识别和理解宿主与微生物群的相互作用以及促成这些相互作用的因素，可能会促进旨在恢复宿主与微生物群稳态的新型治疗策略的发展。在这篇综述中，我们讨论了关于呼吸道中宿主与微生物群相互作用的最新文献，特别关注内源性宿主防御肽和蛋白质（HDPs）对体内微生物群组成的影响，并探讨了针对慢性炎症性肺病中微生物群失调的可能的与HDPs相关的治疗方法。
